Glaxosmithkline Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
GlaxoSmithKline Pharmaceuticals is strategically pivoting towards an innovation-led growth model, focusing on oncology, respiratory therapies, and adult vaccines as primary growth drivers. Management's commitment to double-digit revenue growth, supported by a robust pipeline of new product launches, aligns with Vista's forecast of accelerating revenue growth beyond historical levels. The company's operational simplification and disciplined cost management are expected to maintain stable margins, despite elevated operational expenses associated with new launches. However, risks such as regulatory challenges and reliance on the acute segment could impact profitability. The favorable currency environment and strong demand for chronic therapies provide additional support for revenue stability. Over the next 12-24 months, key opportunities include the successful launch of innovative products and expansion into new therapeutic areas, while watchpoints include potential margin pressures from rising input costs and competitive dynamics in the biosimilars market. Overall, Vista's outlook reflects a balanced view, anticipating continued growth driven by strategic investments in high-margin segments while remaining cautious of external pressures
Why We Like This Stock
- Management's pivot towards high-margin oncology and respiratory therapies is expected to drive double-digit revenue growth
- A robust pipeline of innovative products, including new vaccines and therapies, supports Vista's forecast of accelerating revenue growth
- Favorable currency conditions and strong demand for chronic therapies enhance revenue stability
Things To Watch Out For
- Regulatory challenges and reliance on the acute segment may pose risks to profitability
- Elevated operational expenses related to new product launches could pressure margins in the short term
- Increased competition in the biosimilars market may impact profitability and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,454 | 3,749 | 3,822 | 4,099 | 4,549 |
| Profit Before Tax (Cr.) | 910 | 1,187 | 1,385 | 1,429 | 1,617 |
| PBT Margin | 26.3% | 31.7% | 36.2% | 34.9% | 35.5% |
| Net Profit (Cr.) | 646 | 880 | 1,030 | 1,067 | 1,208 |
| Earnings Per Share | 38.1 | 52.0 | 60.8 | 63.0 | 71.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Motilal Oswal | ► Neutral | 2,870 | 05-Aug-2026 |
Company Overview
Show Company Profile
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.